[Rational and cost effective osteoporosis prevention and therapy]

Internist (Berl). 2002 Apr;43(4):554-62. doi: 10.1007/s001080100415.
[Article in German]
No abstract available

MeSH terms

  • Aged
  • Cost-Benefit Analysis
  • Diphosphonates / economics
  • Diphosphonates / therapeutic use*
  • Female
  • Fluorides / economics
  • Fluorides / therapeutic use*
  • Humans
  • Middle Aged
  • Osteoporosis, Postmenopausal / drug therapy*
  • Osteoporosis, Postmenopausal / economics
  • Raloxifene Hydrochloride / economics
  • Raloxifene Hydrochloride / therapeutic use*

Substances

  • Diphosphonates
  • Raloxifene Hydrochloride
  • Fluorides